Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.58 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.54 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.54 |
| ▸ | MRGPRX4 | Q96LA9 | 6/20 | 0.53 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4399149 | 0.88 | MRGPRX4 (0.50) | MRGPRX4SLC7A5RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL32665365 | 0.85 | NQO2 (0.44) | SLC7A5RAB9AKDM4EMAPTNPC1 | |
| SCHEMBL4396144 | 0.82 | SLC7A5 (0.43) | LOXL2CYP4F2CYP4A11MRGPRX4SLC7A5 | |
| SCHEMBL879574 | 0.82 | LOXL2 (0.56) | LOXL2CYP4F2CYP4A11MRGPRX4SLC7A5 | |
| SCHEMBL716007 | 0.81 | NPC1 (0.56) | RAB9ANPC1 | |
| SCHEMBL2141158 | 0.80 | LOXL2 (0.54) | LOXL2CYP4F2CYP4A11MRGPRX4SLC7A5 | |
| SCHEMBL31539425 | 0.80 | CYP4F2 (0.59) | LOXL2CYP4F2CYP4A11MRGPRX4SLC7A5 | |
| SCHEMBL2996602 | 0.80 | CYP4F2 (0.59) | LOXL2CYP4F2CYP4A11MRGPRX4SLC7A5 | |
| SCHEMBL21221834 | 0.79 | MRGPRX4 (0.64) | LOXL2MRGPRX4RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL4982689 | 0.79 | SLC7A5 (0.50) | LOXL2CYP4F2CYP4A11MRGPRX4SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1986694-B1 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS | NOVO NORDISK HEALTHCARE AG (CH) | 2015-06-10 | — | — | EP | disclosed |
| US-20140045753-A1 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS | NOVO NORDISK HEALTH CARE AG (CH) | 2014-02-13 | — | — | US | disclosed |
| US-20140045753-A1 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS | NOVO NORDISK HEALTH CARE AG (CH) | 2014-02-13 | — | — | US | disclosed |
| US-20140045753-A1 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS | NOVO NORDISK HEALTH CARE AG (CH) | 2014-02-13 | — | — | US | disclosed |
| US-20090105134-A1 | C-Terminally Pegylated Growth Hormones | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| US-20090105134-A1 | C-Terminally Pegylated Growth Hormones | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| US-20090105134-A1 | C-Terminally Pegylated Growth Hormones | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| US-20090082254-A1 | Coupling of Polypeptides at the C-Terminus | NOVO NORDISK A/S (DK) | 2009-03-26 | — | — | US | disclosed |
| US-20090082254-A1 | Coupling of Polypeptides at the C-Terminus | NOVO NORDISK A/S (DK) | 2009-03-26 | — | — | US | disclosed |
| EP-1986694-A1 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS | Novo Nordisk A/S (DK) | 2008-11-05 | — | — | EP | disclosed |
| EP-1850878-A2 | C-TERMINALLY PEGYLATED GROWTH HORMONES | NOVO NORDISK A/S (DK) | 2007-11-07 | — | — | EP | disclosed |
| WO-2007093594-A1 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS | NOVO NORDISK HEALTH CARE AG (DK) | 2007-08-23 | — | — | WO | disclosed |
| WO-2006084888-A2 | C-TERMINALLY PEGYLATED GROWTH HORMONES | NOVO NORDISK A/S (DK) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082254-A1 | Coupling of Polypeptides at the C-Terminus | PTMS, VIP, LNPEP | LOXL2 3513/4885CYP4F2 4128/4885CYP4A11 4765/4885 |
| US-20140045753-A1 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS | PTMS, VIP, LNPEP | LOXL2 3513/4885CYP4F2 4128/4885CYP4A11 4765/4885 |
| US-20090105134-A1 | C-Terminally Pegylated Growth Hormones | GHRHR, GHITM, HDGF | LOXL2 3549/4885CYP4F2 2488/4885CYP4A11 2590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.